REDX
PHARMA PLC
("Redx"
or the "Company")
Share Purchases by a
Director
Alderley Park, UK, 18 April
2024 Redx (AIM:REDX), the
clinical-stage biotechnology company focused on discovering and
developing novel, small molecule, targeted therapeutics for the
treatment of fibrotic disease and cancer today announces that it
has been notified that Lisa Anson, Chief Executive Officer, has on
16 and 17 April 2024 acquired 189,500 Redx ordinary shares at a
weighted average price of 10.01 pence per share. Following
this, Lisa Anson will hold 751,683 ordinary shares in the Company,
representing 0.19 per cent. of the issued share capital.
Further information on the purchases
is contained within the disclosure tables below.
|
For
further information, please contact:
|
|
|
|
|
|
|
|
|
|
Redx
Pharma Plc
UK
Headquarters
Caitlin Pearson, Head of
Communications
ir@redxpharma.com
|
T: +44 (0)1625 469 918
|
|
SPARK Advisory Partners (Nominated Adviser)
|
T: +44 (0)203 368 3550
|
|
Matt Davis/ Adam Dawes
|
|
|
|
|
|
Panmure Gordon (UK) Limited (Broker)
|
T: +44 (0)207 886 2500
|
|
Rupert Dearden/ Freddy Crossley/ Emma
Earl
|
|
|
|
|
|
FTI
Consulting
|
T: +44 (0)203 727 1000
|
|
Simon Conway/ Ciara Martin
|
|
|
|
|
|
|
|
About Redx Pharma Plc
Redx Pharma (AIM: REDX) is a
clinical-stage biotechnology company focused on the discovery and
development of novel, small molecule, targeted therapeutics for the
treatment of fibrotic disease, cancer and the emerging area of
cancer-associated fibrosis. Redx aims to progress its programmes to
clinical proof of concept before evaluating options for further
development and potential value creation. The Company expects a
number of data points during 2024 including from lead fibrosis
product candidate, the selective ROCK2 inhibitor, zelasudil
(RXC007), in development for interstitial lung disease and
currently undertaking a Phase 2a trial for idiopathic pulmonary
fibrosis (IPF). The Company's second fibrosis
candidate, RXC008, a GI-targeted ROCK inhibitor for the
treatment of fibrostenotic Crohn's disease, is in Phase 1
development and is expected to report healthy volunteer data; and
Redx's lead oncology product candidate, the Porcupine inhibitor
zamaporvint (RXC004), being developed as a targeted treatment for
Wnt-ligand dependent cancers, is expected to report anti-PD-1
combination Phase 2 data, following which Redx will seek a partner
for ongoing development.
The Company has a strong track
record of discovering new drug candidates through its core
strengths in medicinal chemistry and translational science,
enabling the Company to discover and develop differentiated
therapeutics against biologically or clinically validated targets.
The Company's accomplishments are evidenced not only by its
wholly-owned clinical-stage product candidates and discovery
pipeline, but also by its strategic transactions, which includes
the sale of pirtobrutinib (RXC005, LOXO-305), the only non-covalent
or reversible BTK inhibitor now approved by the US FDA, and
transactions with both AstraZeneca and Jazz
Pharmaceuticals.
To subscribe to Email Alerts from
Redx, please visit: www.redxpharma.com/investor-centre/email-alerts/.
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them
|
1.
|
Details of the person discharging managerial responsibilities
(PDMR) / person closely associated
|
|
a)
|
Name
|
Lisa Anson
|
|
2.
|
Reason for the notification
|
|
a)
|
Position / status
|
Chief Executive
Officer
|
|
b)
|
Initial notification /
Amendment
|
Initial
notification
|
|
3.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction
monitor
|
|
a)
|
Name
|
Redx Pharma plc
|
|
b)
|
LEI
|
213800HMS4EBXO589Y37
|
|
4
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial
instrument, type of instrument
Identification code
|
Ordinary Shares of 1 pence each in
Redx Pharma plc
ISIN for Redx Pharma plc Ordinary
Shares:
GB00BSNB6S51
|
|
b)
|
Nature of the
transaction
|
Purchase of Ordinary
Shares
|
|
c)
|
Prices(a) and
volume(s)
|
|
Purchase Price per Ordinary
Share
|
Volume
|
|
|
|
|
9.375 pence
|
115,000 Ordinary Shares
|
|
|
d)
|
Aggregated
information
- Aggregated volume
- Price
|
115,000
9.375p
|
|
e)
|
Date of the
transaction
|
16 April 2024
|
|
f)
|
Place of the
transaction
|
London Stock Exchange, AIM Market
(XLON)
|
|
1.
|
Details of the person discharging managerial responsibilities
(PDMR) / person closely associated
|
|
a)
|
Name
|
Lisa Anson
|
|
2.
|
Reason for the notification
|
|
a)
|
Position / status
|
Chief Executive
Officer
|
|
b)
|
Initial notification /
Amendment
|
Initial
notification
|
|
3.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction
monitor
|
|
a)
|
Name
|
Redx Pharma plc
|
|
b)
|
LEI
|
213800HMS4EBXO589Y37
|
|
4
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial
instrument, type of instrument
Identification code
|
Ordinary Shares of 1 pence each in
Redx Pharma plc
ISIN for Redx Pharma plc Ordinary
Shares:
GB00BSNB6S51
|
|
b)
|
Nature of the
transaction
|
Purchase of Ordinary
Shares
|
|
c)
|
Prices(a) and
volume(s)
|
|
Purchase Price per Ordinary
Share
|
Volume
|
|
|
|
|
11 pence
|
74,500 Ordinary Shares
|
|
|
d)
|
Aggregated
information
- Aggregated volume
- Price
|
74,500
11p
|
|
e)
|
Date of the
transaction
|
17 April 2024
|
|
f)
|
Place of the
transaction
|
London Stock Exchange, AIM Market
(XLON)
|
